Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre
Authors' conclusion
JDM and AoDM are not merely age-defined variants but display distinct clinical, serological and prognostic profiles.
Study context
- Population
- Patients with DM meeting the 2017 EULAR/ACR classification criteria, followed 1995–2025 at a tertiary referral centremedian follow-up 5.9 years
- Participants
- 180 patients
- Exposure
- JDM vs AoDM
- JDMn = 86
- AoDMn = 94reference
- Outcome
- Age-related differences in clinical features, serological profiles, diagnostic approaches, treatment strategies and outcomes
Methodological detailssingle tertiary referral centre, paediatric and adult rheumatology clinics
- Single tertiary referral centre
- Paediatric and adult rheumatology clinics
Main finding
As reported in the abstract
Calcinosis
JDM
33%
AoDM
1
events
P = 0.007
Observational data: associations, not effects.
Further findings
Steroid-free remission · reported as higher in JDM
P = 0.020
Drug-free remission · higher in JDM
P = 0.020
Leading autoantibody
anti-NXP2, n tested JDM 35
Anti-synthetase antibodies, n tested AoDM 26
| Outcome | OR (95% CI) | |
|---|---|---|
| Mortality, by age at diagnosis (per year)Independently associated | 1.07 (1.02–1.11) | |
| Malignancy, by age at diagnosis (per year)Independently associated | 1.05 (1.00–1.10) | |
| 0.512Odds ratio (log scale) |
| Outcome | JDM | AoDM |
|---|---|---|
| Malignancy-associated DM | — not stated in the abstract | 26.6% |
— not stated in the abstract
- Arthritis · arthritis significantly associated with JDM
- P = 0.049
Malignancy-associated DM
- Occurred only in AoDM
Original publication
Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary centre. Rheumatology (Oxford). Published 20 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →